17:02 EST Xoma (XOMA) to acquire Generation Bio (GBIO) for $4.2913 per share
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on XOMA:
- Buy Rating Maintained for XOMA Despite Rezolute Bio’s Trial Setback, Future Developments Anticipated
- Xoma price target lowered to $97 from $104 at H.C. Wainwright
- Xoma’s Resilience and Growth Potential: Analyst Reaffirms Buy Rating Amidst Diversified Portfolio and Strong Financial Health
- Xoma price target lowered to $45 from $58 at Leerink
- Xoma falls 21% after partner Rezolute announces trial failure